Look who stopped by to discuss the role of MRD in lymphoma! Thanks Dr. Merryman for all the great insights. Read up on his session HERE: targetedonc.com/view/improved-… #SOHO2024 | Society of Hematologic Oncology (SOHO) Dana-Farber

In a presentation during #SOHO2024, Reid W. Merryman, MD, discussed the latest developments with MRD assays in the management of patients with #lymphoma. #LYMSM | Dana-Farber Society of Hematologic Oncology (SOHO) targetedonc.com/view/improved-…

Huge thanks to Greg from @mayoclinic for joining us to discuss current approaches and updates on ongoing trials in frontline #DLBCL:! We appreciate the valuable insights and expertise. 🩺 #SOHO2024 | Society of Hematologic Oncology (SOHO)

Dr. Kebriaei shared some great insights during this session at #SOHO2024 AND during an exclusive interview with Targeted Oncology. Learn more about transplant in #ALL HERE: targetedonc.com/view/transplan… | Society of Hematologic Oncology (SOHO) MD Anderson Cancer Center

Targeted therapy based on genetic information led to longer progression-free survival than traditional chemotherapy in a recent study. Read more: targetedonc.com/view/molecular…

We had the pleasure of speaking with John Seymour, MBBS, FRACP, PhD, of Peter Mac Cancer Centre today at #SOHO2024 on BCL2 Inhibition in #CLL. Stay tuned on our site to learn more about this exciting era in CLL! targetedonc.com/conference/soho

Anil Parwani, MD, PhD, discusses how the use of artificial intelligence technology can be integrated into the current workflow of pathologists. The Ohio State University College of Medicine targetedonc.com/view/utilizing…

Findings presented at #SOHO2024 showed that there was an 11% decrease from 2018 to 2022 in patients receiving tisagenlecleucel in the third or later relapse. #LEUSM | Society of Hematologic Oncology (SOHO) BCMHouston targetedonc.com/view/tisa-cel-…

Starting the day off with a T-cell lymphoma session chaired by Dr. Moskowitz and Neha Mehta-Shah. Pictured: Dr. O’Connor discussing some exciting novel therapies! Looking forward to even more! #SOHO2024 | Society of Hematologic Oncology (SOHO)

Imetelstat has shown promising results in maintaining red blood cell transfusion independence in patients with lower-risk #MDS, according to data from the phase 3 IMerge trial presented at #SOHO2024. Valeria Santini Society of Hematologic Oncology (SOHO) targetedonc.com/view/imetelsta…

Dr. Craig Portell of UVA Cancer Center gave us a sneak peak into the session he is a part of later today on sequencing therapies in #MCL at #SOHO2024! Stay tuned for his insights👀 Society of Hematologic Oncology (SOHO)

At #SOHO2024, Elias Jabbour, MD, of MD Anderson Cancer Center noted that a significant proportion of patients with CML-CP can expect to have a normal lifespan. Read more: targetedonc.com/view/moving-la…

2 more great interviews with Drs. Stephen Ansell of Mayo Clinic and Alessandra Ferrajoli of MD Anderson Cancer Center at #SOHO2024! Thank you for sharing your knowledge with us here at Targeted Oncology! Society of Hematologic Oncology (SOHO)

Our Executive VP of Insights and Impact, Claire Saxton, discussed findings from our AML study with Targeted Oncology. Watch the full video: targetedonc.com/view/understan…

Wrapping up our time here at #SOHO2024 with some more great interviews. Thank you Drs. Bose and Litzow for stopping by to chat! Always a pleasure! Society of Hematologic Oncology (SOHO) Mark Litzow Mayo Clinic Prithviraj Bose MD Anderson Cancer Center

WATCH: Craig A. Portell, MD, previews his session on sequencing therapies in relapsed/refractory mantle cell lymphoma being presented at the #SOHO2024. #MCL | UVA Cancer Center Society of Hematologic Oncology (SOHO) targetedonc.com/view/-sequenci…

The #FDA has approved the first ready-to-use administration of subcutaneous bortezomib. targetedonc.com/view/fda-appro…

WATCH: Anil Parwani, MD, PhD, discusses the use of artificial intelligence technology to enhance cancer diagnostics and treatment. The Ohio State University College of Medicine targetedonc.com/view/enhancing…